My WebLink
|
Help
|
About
|
Sign Out
Home
Browse
Search
2023-140
CBCC
>
Official Documents
>
2020's
>
2023
>
2023-140
Metadata
Thumbnails
Annotations
Entry Properties
Last modified
8/4/2023 12:08:17 PM
Creation date
8/4/2023 12:06:37 PM
Metadata
Fields
Template:
Official Documents
Official Document Type
Agreement
Approved Date
07/11/2023
Control Number
2023-140
Agenda Item Number
8.T.
Entity Name
RxBenefits. Inc. f/k/a Prescription Benefits, Inc
Subject
Addendum to Administrative Service Agreement reflecting improved pricing
and updates effective January1, 2023
There are no annotations on this page.
Document management portal powered by Laserfiche WebLink 9 © 1998-2015
Laserfiche.
All rights reserved.
/
23
PDF
Print
Pages to print
Enter page numbers and/or page ranges separated by commas. For example, 1,3,5-12.
After downloading, print the document using a PDF reader (e.g. Adobe Reader).
View images
View plain text
DocuSign Envelope ID: 5332467E-CBEF-4C5D-8B0E-61E380BDAl1B <br />DocuSign Envelope ID: 151ECOCF-B55C-414F-9455-72004347A310 <br />(1/2023 Version) <br />16. ESI will provide the above-mentioned extract at no charge to Client. <br />17. At no charge, ESI must be able to transfer data to Client's other vendor partners (e.g., medical plan <br />administrator, stop loss vendor, disease management vendor, catastrophic claimant advocate, etc.), with an <br />appropriate non -disclosure agreement in place. <br />18. ESI can provide the fully identified NCPDP expanded format to Client's consultant on a monthly basis at no <br />additional charge for use by both the InfoLock team and the Pharmacy Analytics Team. <br />19. InfoLock Data and Pharmacy Analytics team feeds that are in place will be honored even after termination at <br />no cost to Client or Client's consultant. In other words, if the Agreement is not renewed following the Term, <br />InfoLock must still receive the 4th quarter data even though it will not be available until after termination of <br />this Agreement. <br />AUDITS <br />20. Third Party Audits- Client may employ a third -party auditor, at Client's sole cost and expense, to conduct <br />audits of the terms of this Exhibit A, including, but not limited to: <br />Pharmacy Claims transactions <br />Financial performance guarantees <br />21. Client's consultant (Lockton) may perform a pre -implementation audit prior to the Effective Date. <br />MISCELLANEOUS <br />22. Any costs bidding entities may incur as it relates to attending meetings, site visits or negotiations are the <br />responsibility of Administrator. <br />23. Client may not terminate this Agreement without cause and may only terminate this Agreement as expressly <br />provided for in Article VI of the Agreement. <br />24. Coordination of Benefits claims accounted for in the claims data and discount guarantees by a flag indicating <br />that a transaction utilized COB functionality within the RxCLAIM system. COB claims are excluded from <br />pricing guarantees but are assessed an administrative fee if applicable. <br />H. EXECUTION BY CLIENT <br />Client hereby represents and warrants that the information contained in Section A of this Client Application <br />is true and correct in all respects and Client hereby agrees to the specific terms, conditions and financial arrangements <br />set out in this Exhibit A (Client Application). Client agrees that if any information in Section A changes, Client will <br />give Administrator prompt notice of such changes. Furthermore, Client understands that this Exhibit A (Client <br />Application) is a part of the Administrative Services Agreement between Client and Administrator to which it is <br />attached and incorporated into by reference and that Client is bound by all terms and conditions of such Administrative <br />Services Agreement. <br />All capitalized terms used in this Exhibit A (Client Application) but not specifically defined herein shall have <br />the meanings given to such terms in the Administrative Services Agreement to which this Exhibit A (Client <br />Application) is attached and made a part of. <br />22 <br />NOT FOR DISTRIBUTION. THE INFORMATION CONTAINED HEREIN IS CONFIDENTIAL, PROPRIETARY <br />AND CONSTITUTES TRADE SECRETS OF ESI AND RXBENEFITS <br />
The URL can be used to link to this page
Your browser does not support the video tag.